通心络治疗冠心病心力衰竭34例患者血栓素b2及脂 质变化的临床意义（Clinical significance of Tongxinluo on the changes of thromboxane B2 and lipid in 34 patients with coronary heart disease and heart failure）.docVIP

通心络治疗冠心病心力衰竭34例患者血栓素b2及脂 质变化的临床意义（Clinical significance of Tongxinluo on the changes of thromboxane B2 and lipid in 34 patients with coronary heart disease and heart failure） Clinical significance of Tongxinluo on the changes of thromboxane B2 and lipid in 34 patients with coronary heart disease and heart failure Update Date: 2009-04-19 click: Jin Heng, Shi Haifeng Objective To observe the changes of thromboxane B2 (TXB2) and serum lipid levels in 34 patients with coronary heart disease and heart failure after oral Tongxinluo treatment, and compare them with 34 cases in the routine treatment group. After 1 courses of treatment, the concentration of TXB2, glycerin three (TG) and total cholesterol (TC) in the observation group were significantly improved (P 0.01), compared with the control group (P 0.05). The observation shows that Tongxinluo capsule has good effect on reducing blood viscosity, improving microcirculation, relieving illness and improving curative effect in patients with coronary heart disease. Keywords Tongxinluo; heart failure; thromboxane B2; blood lipid; Classification number: R 286, document identification code: A, article number: 1007-5615 (2000) 01-0034-02 Tongxinluo is a traditional Chinese medicine compound capsule prepared by various kinds of pure Chinese medicine. 34 cases of coronary heart disease and heart failure were treated with Tongxinluo, and the results of thromboxane B2 and blood lipid analysis were as follows. 1 data and methods 1.1 objects (observation group) 34 patients with heart failure in the observation group, including coronary heart disease in 34 cases, including hyperlipidemia and coronary heart disease in 17 cases, male 19 cases, female 15 cases, age 45~74 years old, average 62.1 years old. Among them, 21 patients with left ventricular function were grade II to III, and 13 patients with grade IV (all accord with cardiac function classification of American Heart Association in 1994). Of the 30 patients in the control grou